Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2026)

Xeris Biopharma Holdings has reported Common Equity for 7 years, with the latest figure at $13.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 137.04% year-over-year to $13.0 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (up 137.04% YoY), and the FY2025 full-year result was $13.7 million, up 146.22% from the prior year.
• Common Equity for Q1 2026 stood at $13.0 million, down from $13.7 million in the prior quarter.
• The five-year high for Common Equity was $96.5 million in Q1 2022, with the low at -$35.1 million in Q1 2025.
• Historically, Common Equity has averaged $11.6 million across 5 years, with a median of $3.9 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity soared 2336.49% — and 2024, when it plunged 832.81%.
• Xeris Biopharma Holdings' Common Equity stood at $45.2 million in 2022, then tumbled by 115.01% to -$6.8 million in 2023, then slumped by 336.67% to -$29.6 million in 2024, then surged by 146.22% to $13.7 million in 2025, then fell by 4.95% to $13.0 million in 2026.
• The last three Common Equity figures came in at $13.0 million (Q1 2026), $13.7 million (Q4 2025), and -$861000.0 (Q3 2025), per Business Quant data.